Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials

Published:2018-03-07 Issue:4 Volume:18 Page:271-282
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Wang Yang,Wang Jinsong,Wang Shenming

Funder

National Natural Science Fund

Science and Technology Planning Project of Guangdong Province

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/article/10.1007/s40256-018-0270-7/fulltext.html

Reference35 articles.

1. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31:236–44.

2. DiNicolantonio JJ, Lavie CJ, Serebruany VL, Serebruany VL, O’Keefe JH, O’Keefe JH. Statin wars: the heavyweight match–atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013;125:7–16.

3. Deedwania PC. Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med. 2014;126:29–36.

4. Ducobu J, Scheen A, Van Gaal L, et al. Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. Acta Cardiol. 2008;63:235–48.

5. Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;1(37):1373–9.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients;Expert Opinion on Drug Safety;2023-12-08

2. Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews;Medicine;2023-01-20

3. PCSK9 Inhibition: From Current Advances to Evolving Future;Cells;2022-09-23

4. Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica;Archivos de Cardiología de México;2022-03-14

5. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies;American Heart Journal Plus: Cardiology Research and Practice;2022-01